News

Solara Active Pharma Sciences has allotted 2,200 equity shares under ESOP on 15 May 2026. With this allotment, the paid up equity share capital has increased to 4,81,73,762 equity shares at Rs. 10/- each.

Net profit of Solara Active Pharma Sciences reported to Rs 9.60 crore in the quarter ended March 2026 as against net loss of Rs 2.10 crore during the previous quarter ended March 2025. Sales rose 41.86% to Rs 387.29 crore in the quarter ended March 2026 as against Rs 273.01 crore during the previous quarter ended March 2025.For the full year,net loss reported to Rs 7.41 crore in the year ended March 2026 as against net profit of Rs 0.54 crore during the previous year ended March 2025. Sales rose 6.64% to Rs 1368.98 crore in the year ended March 2026 as against Rs 1283.76 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales387.29273.01 42 1368.981283.76 7 OPM %14.8916.62 -13.6416.07 - PBDT34.7822.20 57 98.1699.79 -2 PBT8.74-2.10 LP -1.520.54 PL NP9.60-2.10 LP -7.410.54 PL Powered by Capital Market - Live News

Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 15 May 2026.

Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 24 March 2026.Powered by Capital Market - Live News

Net loss of Solara Active Pharma Sciences reported to Rs 17.43 crore in the quarter ended December 2025 as against net profit of Rs 8.09 crore during the previous quarter ended December 2024. Sales rose 16.21% to Rs 349.00 crore in the quarter ended December 2025 as against Rs 300.31 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales349.00300.31 16 OPM %10.7019.21 - PBDT14.8932.63 -54 PBT-10.688.09 PL NP-17.438.09 PL Powered by Capital Market - Live News